Key facts
- This page summarizes Myron Czuczman's Form 4 filing for Citius Pharmaceuticals, Inc. (CTXR).
- 1 reported transaction and 5 derivative rows are listed below.
- Accepted by SEC: 12 Nov 2024, 17:00.
Myron Czuczman - 07 Nov 2024 Form 4 Insider Report for Citius Pharmaceuticals, Inc. (CTXR)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- CTXR
- Reported as of
- 07 Nov 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Nov 2024, 17:00:23 UTC
- Prior SEC filing
- 14 Aug 2024
- Next SEC filing
- 16 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alexander M. Donaldson, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Myron Czuczman filed Form 4 for Citius Pharmaceuticals, Inc. (CTXR) on 12 Nov 2024.
Change
- Previous filing in this sequence was filed on 14 Aug 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CTXR
transaction
Derivative
Stock Option (Right to Purchase Common Stock)
Award
- Transaction value
- $0
- Shares
- +300,000
- Change %
- Price
- $0.000000
- Shares after
- 300,000
- Date
- 07 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 300,000
- Exercise price
- $0.3800
- Footnotes
- F1
CTXR
holding
Derivative
Stock Option (Right to Purchase Common Stock)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 300,000
- Date
- 07 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 300,000
- Exercise price
- $0.7000
- Footnotes
- F2
CTXR
holding
Derivative
Stock Option (Right to Purchase Common Stock)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 300,000
- Date
- 07 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 300,000
- Exercise price
- $1.25
- Footnotes
- F3
CTXR
holding
Derivative
Stock Option (Right to Purchase Common Stock)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 300,000
- Date
- 07 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 300,000
- Exercise price
- $2.04
- Footnotes
- F4
CTXR
holding
Derivative
Stock Option (Right to Purchase Common Stock)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 500,000
- Date
- 07 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 500,000
- Exercise price
- $1.19
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The options were granted on November 7, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
Footnote F2
The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
Footnote F3
The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
Footnote F4
The options are fully vested and exercisable immediately.